$83.40
-1.98 (-2.32%)
Open$84.01
Previous Close$85.38
Day High$87.10
Day Low$83.07
52W High$91.00
52W Low$10.77
Volume—
Avg Volume1.26M
Market Cap4.36B
P/E Ratio—
EPS$-2.39
SectorBiotechnology
Analyst Ratings
Strong Buy
20 analysts
Price Target
-75.2% upside
Current
$83.40
$83.40
Target
$20.70
$20.70
$16.39
$20.70 avg
$27.30
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 372.50M | 351.85M | 301.99M |
| Net Income | -104,674,461 | -84,234,881 | -79,583,487 |
| Profit Margin | -28.1% | -23.9% | -26.4% |
| EBITDA | -120,858,001 | -107,157,018 | -93,330,324 |
| Free Cash Flow | -75,919,374 | -55,757,162 | -73,499,960 |
| Rev Growth | -6.8% | +18.4% | +6.2% |
| Debt/Equity | 0.83 | 0.74 | 0.81 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $243.73 | +3.76% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $356.32 | +1.39% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $124.43 | -0.58% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $484.49 | +1.96% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $625.11 | +0.27% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $291.90 | -0.73% | 64.3 | 37.13B |